Eli Lilly (LLY) made headlines with positive results from the Phase 3 BRUIN CLL-314 clinical trial for Jaypirca, marking a significant advancement in treatment options for chronic lymphocytic leukemia ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly and Company (NYSE:LLY) is one of the Stocks With Huge Catalysts on the Horizon. On July 21, Eli Lilly and Company ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly ( LLY 0.14%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...

Through an analysis of Eli Lilly, we can infer the following trends: At 86.87, the stock's Price to Earnings ratio significantly exceeds the industry average by 3.52x, suggesting a premium ...

Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance Eli Lilly sees FY24 EPS $12.20-$12.70, consensus $12.43 Eli Lilly reports Q4 EPS $2.49, consensus $2.19 ...

Eli Lilly is serving a market that may reach $100 billion. Eli Lilly (LLY 0.16%) stock has soared 90% over the past year, a huge gain for a pharmaceutical company.

The stock’s shares went for about $868 in early June, up more than 93 percent over the last year. Bottom line Eli Lilly’s stock price is riding a wave of optimism and strong earnings.

However, when looking at the fundamental performance of these two, I don’t see many reasons for the stock outperformance of Eli Lilly. At best, we can call it a head-to-head race.

Eli Lilly (NYSE: LLY) stock has soared 90% over the past year, a huge gain for a pharmaceutical company. These stocks generally are known for steady increases over time instead of big movements ...